盐酸埃克替尼治疗EGFR突变晚期肺腺癌的预后因素分析

目的 探讨晚期肺腺癌表皮生长因子受体（EGFR）突变患者应用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）盐酸埃克替尼片治疗与预后的关系。方法 入组河北省胸科医院基因检测提示EGFR19、21基因突变且接受盐酸埃克替尼片治疗的晚期肺腺癌患者，分析其临床特征、EGFR基因突变亚型及不同位点与预后的关系。结果 全组共纳入101例晚期肺腺癌患者，EGFR基因19外显子缺失突变（EGFR Del19）58例，21外显子点突变（EGFR L858R）43例。全组患者客观缓解率达63.4%，中位无疾病进展时间（mPFS）和中位生存时间（mOS）分别为13个月和27个月。EGFR Del19对比EGFRL858R及EGFR19突变746~750位点对比其他突变位点的患者mPFS和mOS均增高。多因素分析显示，转移部位数和有无胸膜转移为OS的独立影响因素（P=0.027, P=0.041），转移部位数≤3和无胸膜转移组患者的mOS分别为29个月和27个月。结论 盐酸埃克替尼片治疗晚期肺腺癌患者EGFR不同突变亚型和位点总生存差异不显著，转移部位数≤3和无胸膜转移的患者总生存期更长。

Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib

Objective To investigate the relationship between the treatment of EGFR-TKI icotinib and the prognosis of advanced lung adenocarcinoma patients with EGFR mutation. Methods Patients with advanced lung adenocarcinoma who had EGFR19 and 21 gene mutations and were treated with EGFR-TKI icotinib were enrolled. The relationships of clinical features, EGFR gene mutation subtypes, and different sites with patients' prognosis were analyzed. Results A total of 101 patients with advanced lung adenocarcinoma were included in this study, including 58 cases (57.4%) of EGFR gene exon 19 deletion mutation (EGFR Del19) and 43 cases (42.6%) of EGFR gene exon 21 point mutation (EGFR L858R). The objective response rate was 63.4%. The mPFS and mOS were 13 months and 27 months, respectively. In addition, the mPFS and mOS of EGFR Del19 and EGFR19 mutation 746-750 were higher than those of EGFR L858R and other EGFR mutations, respectively. Meanwhile, multivariate analysis showed that the number of metastatic sites and pleural metastasis were independent influencing factors of patients' OS (P=0.027; P=0.041). The mOS of patients with the number of metastatic sites ≤3 and without pleural metastasis were 29 and 27 months, respectively. Conclusion There is no significant difference found in overall survival of advanced lung adenocarcinoma patients treated with icotinib among different EGFR mutation subtypes and sites. Herein, the overall survival time is longer in patients with less than three metastatic sites and without pleural metastasis.